G1 Therapeutics(GTHX) - 2023 Q4 - Earnings Call Transcript

What we are doing is certainly monitoring the FDA website to make sure that it doesn't - we don't see a repeat in '24, what we saw in '23. And certainly, at the clinic level, what we've heard from really late Q3 is that customers are not having issue, being able to access any of the carbo or cisplatinum. Operator Andrew Perry I think as we move forward into market expansion into new indications, we would reevaluate that. But I don't see it being like a real phase shift I see it being an evolution of the tea ...